Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Senti Biosciences Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Senti Biosciences Holdings, Inc.’s stock price such as:

• Senti Biosciences Holdings, Inc.’s current stock price and volume
• Why Senti Biosciences Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for SNTI from analysts
• SNTI’s stock price momentum as measured by its relative strength

About Senti Biosciences Holdings, Inc. (SNTI)

Before we jump into Senti Biosciences Holdings, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company’s lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Want to learn more about Senti Biosciences Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Senti Biosciences Holdings, Inc..

Senti Biosciences Holdings, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Senti Biosciences Holdings, Inc.’s stock price was $0.341.

Senti Biosciences Holdings, Inc. is down 5.52% from its previous closing price of $0.360.

During the last market session, Senti Biosciences Holdings, Inc.’s stock traded between $0.340 and $0.380. Currently, there are approximately 30.97 million shares outstanding for Senti Biosciences Holdings, Inc..

Senti Biosciences Holdings, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Senti Biosciences Holdings, Inc. Stock Price History

Senti Biosciences Holdings, Inc.’s (SNTI) price is currently down 69.05% so far this month.

During the month of July, Senti Biosciences Holdings, Inc.’s stock price has reached a high of $1.110 and a low of $0.340.

Over the last year, Senti Biosciences Holdings, Inc. has hit prices as high as $2.880 and as low as $0.343. Year to date, Senti Biosciences Holdings, Inc.’s stock is down 67.26%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Senti Biosciences Holdings, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 30, 2026,, no analysts have changed their rating of Senti Biosciences Holdings, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Senti Biosciences Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Senti Biosciences Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Senti Biosciences Holdings, Inc. (SNTI) by visiting AAII Stock Evaluator.

Relative Price Strength of Senti Biosciences Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Senti Biosciences Holdings, Inc. has a weighted four-quarter relative price strength of -35.40%, which translates to a Momentum Score of 5 and is considered to be Very Weak.

Want to learn more about how Senti Biosciences Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Senti Biosciences Holdings, Inc. Stock Price: Bottom Line

As of July 31, 2026, Senti Biosciences Holdings, Inc.’s stock price is $0.341, which is down 5.52% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Senti Biosciences Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.